Pyrimido[4,5-b]quinoline

Base Information

• Chemical Name: Pyrimido[4,5-b]quinoline
• CAS No.: 261-01-8
• Molecular Formula: C11H7 N3
• DSSTox Substance ID: DTXSID70592689
• Wikidata: Q82486932
• Mol file: 261-01-8.mol

Synonyms:Pyrimido[4,5-b]quinoline;261-01-8;SCHEMBL3261625;DTXSID70592689

Chemical Property of Pyrimido[4,5-b]quinoline

Chemical Property:

• XLogP3: 2.1
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 0
• Exact Mass: 181.063997236
• Heavy Atom Count: 14
• Complexity: 207

Purity/Quality:

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC=C2C(=C1)C=C3C=NC=NC3=N2
• General Description: Pyrimido[4,5-b]quinoline (also known as 2,4-Diazaacridine) derivatives were investigated as part of a series of novel compounds targeting VEGFR tyrosine kinase for anticancer and radiosensitizing effects. These derivatives, along with other quinoline-based compounds, demonstrated potential in inhibiting VEGFR-TK, which plays a role in cancer progression. While specific data on the pyrimido[4,5-b]quinoline derivatives (16–20) were not highlighted in the abstract, the study overall suggests that such compounds may contribute to anticancer activity by disrupting angiogenesis and enhancing radiation efficacy. Further research would be needed to confirm their individual potency and mechanism.

Refernces

Design and synthesis of some novel quinoline derivatives as anticancer and radiosensitizing agents targeting VEGFR tyrosine kinase

10.1002/jhet.749

The study investigates the synthesis and evaluation of novel quinoline derivatives for their anticancer and radiosensitizing properties. The researchers synthesized a series of quinoline derivatives (6–12) and pyrimido[4,5-b]quinoline derivatives (16–20) to assess their potential as inhibitors of vascular endothelial growth factor receptor tyrosine kinase (VEGFR-TK), which is implicated in cancer cell proliferation and angiogenesis. The compounds were evaluated for their in vitro anticancer activity against the human breast cancer cell line MCF7, which overexpresses VEGFR. Notably, compounds 6 and 7 exhibited significant cytotoxic activity, with IC50 values of 8.5 μM and 21.9 μM, respectively, surpassing the reference drug doxorubicin (IC50 = 32.02 μM). These two compounds were further tested for their ability to enhance the cell-killing effect of gamma radiation, showing a synergistic decrease in IC50 values when combined with radiation. The study also utilized molecular modeling to generate a pharmacophore hypothesis for VEGFR-TK inhibitors and conducted docking studies to explore the binding modes of the synthesized compounds, revealing that compound 7 had a binding mode similar to the known VEGFR-TK inhibitor Vatalanib. The results suggest that some of the synthesized compounds may act as VEGFR-TK inhibitors, contributing to their anticancer activity and radiosensitizing effects.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 261-01-8 Pyrimido[4,5-b]quinoline(8CI,9CI)

Send

Send

Metric Ton KG G Pound L ML

Send

Send